AU Patent

AU2020281063A1 — LFA-1 inhibitor and polymorph thereof

Assigned to Novartis AG · Expires 2021-01-07 · 5y expired

What this patent protects

LFA-1 INHIBITOR AND POLYMORPH THEREOF ABSTRACT Methods of preparation and purification of a compound, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed.

USPTO Abstract

LFA-1 INHIBITOR AND POLYMORPH THEREOF ABSTRACT Methods of preparation and purification of a compound, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020281063A1
Jurisdiction
AU
Classification
—
Expires
2021-01-07
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.